1-2 of 2
Hai Hu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Fei Li, Qingyuan Huang, Troy A. Luster, Hai Hu, Hua Zhang, Wai-Lung Ng, Alireza Khodadadi-Jamayran, Wei Wang, Ting Chen, Jiehui Deng, Michela Ranieri, Zhaoyuan Fang, Val Pyon, Catríona M. Dowling, Ece Bagdatlioglu, Christina Almonte, Kristen Labbe, Heather Silver, Alexandra R. Rabin, Kandarp Jani, Aristotelis Tsirigos, Thales Papagiannakopoulos, Peter S. Hammerman, Vamsidhar Velcheti, Gordon J. Freeman, Jun Qi, George Miller, Kwok-Kin Wong
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (2): 270–287.
https://doi.org/10.1158/2159-8290.CD-19-0780
Published: 05 February 2020
View article titled, <em>In Vivo</em> Epigenetic CRISPR Screen Identifies <em>Asf1a</em> as an Immunotherapeutic Target in <em>Kras</em>-Mutant Lung Adenocarcinoma
Open the PDF for <em>In Vivo</em> Epigenetic CRISPR Screen Identifies <em>Asf1a</em> as an Immunotherapeutic Target in <em>Kras</em>-Mutant Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf
Journal: Cancer Discovery
Cancer Discov (2012) 2 (11): 1048–1063.
https://doi.org/10.1158/2159-8290.CD-11-0336
Published: 11 November 2012
View article titled, Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Open the PDF for Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer in another window
Includes: Supplementary data